📈 Revenue History (16 Quarters)
🧮 BBIO Revenue Breakdown
Understanding Revenue
Revenue, also called sales or the "top line," represents the total income a company generates from its business activities before any costs are deducted. For BBIO, the trailing twelve month revenue is $713.1M.
Why Revenue Matters
Revenue is the foundation of all financial analysis. A company cannot have sustainable profits without revenue, and revenue growth often drives stock price appreciation. However, revenue alone doesn't tell the full story - it must be analyzed alongside profitability metrics.
BBIO's revenue growth rate of 100.00% (based on log-linear regression of 16 quarters) indicates strong growth, typical of high-growth companies.
Revenue vs Profitability Metrics
Free Cash Flow: $-445.1M →
The cash remaining after capital expenditures. High revenue with negative FCF may indicate heavy reinvestment or poor cash conversion.
Owner Earnings: $-445.1M →
Buffett's metric for true cash generation. Compares revenue's conversion to actual owner value.
Earnings Per Share: $-3.57 →
Net income per share. The bottom line result of all revenue after costs, taxes, and interest.
Net Income: $-702.0M
What remains after all expenses. Net margin shows what percentage of revenue becomes profit.
Price/Sales Ratio Analysis
BBIO's P/S ratio of 21.1x means investors pay $21.14 for every $1 of annual revenue. A P/S above 10 indicates very high growth expectations.
Gross Margin: Revenue Quality
Gross margin of 94.44% shows how much of BBIO's revenue remains after direct costs. High gross margins above 60% often indicate strong pricing power, brand value, or intellectual property moats.
Summary: BBIO Revenue Trend
BridgeBio Pharma, Inc. (BBIO) generated $713.1M in trailing twelve-month revenue, growing at 100.00% annually — significantly above the 20% threshold Zyberno associates with high-growth businesses. BridgeBio Pharma, Inc.'s gross margin of 94.44% is excellent for a Healthcare company — above the 60% threshold Zyberno applies to healthcare businesses where IP protection, regulatory moats, and service complexity shape gross margins, a level typically associated with strong pricing power and durable competitive advantages. For complete financial analysis, view the full BBIO stock report on Zyberno.
Frequently Asked Questions
What is BBIO's current revenue?
BridgeBio Pharma, Inc.'s trailing twelve month (TTM) revenue is $713.1M, growing at 100.00% annually — significantly above the 20% threshold Zyberno associates with high-growth businesses.
Is BBIO's revenue growing?
BridgeBio Pharma, Inc. (BBIO) generated $713.1M in trailing twelve-month revenue, growing at 100.00% annually — significantly above the 20% threshold Zyberno associates with high-growth businesses. BridgeBio Pharma, Inc.'s gross margin of 94.44% is excellent for a Healthcare company — above the 60% threshold Zyberno applies to healthcare businesses where IP protection, regulatory moats, and service complexity shape gross margins, a level typically associated with strong pricing power and durable competitive advantages.
What is BBIO's gross margin?
BridgeBio Pharma, Inc.'s gross margin of 94.44% is excellent for a Healthcare company — above the 60% threshold Zyberno applies to healthcare businesses where IP protection, regulatory moats, and service complexity shape gross margins, a level typically associated with strong pricing power and durable competitive advantages.
What is BBIO's Price/Sales ratio?
BBIO's P/S ratio is 21.1x, meaning the market values the company at 21.1 times its annual revenue.
How does revenue differ from profit?
Revenue is the total income before any expenses, while profit (net income) is what remains after all costs. BBIO's revenue is $713.1M with a net income of $-702.0M, showing a net profit margin of -98.5%.
📊 Full BBIO Stock Report →
See BBIO's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.
💵 BBIO Free Cash Flow →
Compare to Free Cash Flow which subtracts all capital expenditures, not just maintenance CapEx.
💰 BBIO Owner Earnings →
Compare to Buffett's Owner Earnings metric which uses maintenance CapEx instead of total capital expenditures.
📈 BBIO Earnings Per Share →
Analyze EPS trends, P/E ratio, earnings yield, and per-share profitability metrics.
🎯 BBIO Earnings Surprise (SUE) →
See whether BBIO is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.
📊 BBIO Revenue →
Analyze revenue trends, growth rate, P/S ratio, and top-line sales performance.
💰 BBIO Net Income →
Analyze the bottom-line profit, P/E ratio, and net profit margin trends.
🔶 BBIO Operating Income →
Analyze EBIT, operating margin, and core business profitability before interest and taxes.
💜 BBIO Gross Profit →
Analyze gross margin, pricing power, and profitability before operating expenses.